Breakthrough in Cholesterol Treatment: New Pill Shows Promise
A groundbreaking study has revealed that a new kind of pill, named enlicitide, can significantly reduce artery-clogging cholesterol in individuals who remain at high risk of heart attacks despite taking statins. According to researchers, this experimental pill has shown remarkable results in lowering LDL, or “bad,” cholesterol by as much as 60% over six months.
How Enlicitide Works
Enlicitide works by helping the body rid itself of cholesterol in a way that is currently only possible with injected medicines. This innovative approach has the potential to offer an easier-to-use option for millions of people who require additional help in lowering their LDL cholesterol. Statins, which are the cornerstone of treatment, block some of the liver’s production of cholesterol, but many people need extra support to meet medical guidelines.
Study Findings and Implications
A major study involving over 2,900 high-risk patients found that those who took the enlicitide pill daily saw a substantial drop in their LDL cholesterol levels. The study, published in the New England Journal of Medicine, reported that the benefits of enlicitide persisted over a year, with no significant safety differences between those taking the pill and those taking a placebo. Dr. Ann Marie Navar, a cardiologist at UT Southwestern Medical Center and lead author of the study, noted that “none of the other pills come close to the degree of LDL cholesterol lowering that we see with enlicitide.”
Heart Disease and Cholesterol: A Growing Concern
Heart disease is the nation’s leading cause of death, and high LDL cholesterol is a top risk factor for heart attacks and strokes. The American Heart Association recommends lowering LDL levels to at least 70 for individuals with high cholesterol or heart disease, and even lower for those at very high risk. While statins are effective in lowering LDL, many people require additional treatment, making enlicitide a potentially game-changing option.
Future Prospects and FDA Approval
Merck, the manufacturer of enlicitide, has funded the study and is seeking FDA approval. The FDA has added enlicitide to a program promising ultra-fast reviews, paving the way for potential approval. Dr. William Boden of Boston University and the VA New England Healthcare System, who was not involved in the study, wrote that the research provides “compelling evidence” that enlicitide lowers cholesterol about as much as PCSK9 shots. However, he cautioned that further studies are needed to demonstrate the pill’s effectiveness in reducing heart attacks, strokes, and death.
For more information on this breakthrough study, visit Here
Image Source: www.twincities.com
